Pentose Phosphate Pathway

The pentose phosphate pathway (PPP)—also known as the hexose monophosphate (HMP) shunt or the phosphogluconate pathway—is a universally conserved cytosolic metabolic pathway that operates in parallel to glycolysis, diverting D-glucose-6-phosphate (G6P) to accomplish two primary anabolic and homeostatic objectives without directly generating or consuming adenosine triphosphate (ATP): (1) the generation of cytosolic reduced nicotinamide adenine dinucleotide phosphate (NADPH), which serves as the obligate electron donor for reductive biosyntheses (fatty acid, cholesterol, steroid, and deoxyribonucleotide synthesis) and for the regeneration of reduced glutathione (GSH) against reactive oxygen species (ROS); and (2) the production of D-ribose-5-phosphate (R5P), the phosphoribosyl sugar backbone required for the de novo and salvage synthesis of purine and pyrimidine nucleotides, DNA, RNA, and nucleotide coenzymes (ATP, NAD⁺, FAD, and Coenzyme A), together with D-erythrose-4-phosphate (E4P) for the biosynthesis of aromatic amino acids in plants and microorganisms.

The pathway was elucidated between the mid-1930s and the 1950s through the converging biochemical investigations of Otto Warburg and William Christian (who discovered the coenzyme NADP⁺—originally termed Zwischenferment coferment II—and the oxidation of glucose-6-phosphate in 1935), Fritz Lipmann and Frank Dickens (who demonstrated direct oxidative decarboxylation of 6-phosphogluconate independent of the Embden–Meyerhof–Parnas glycolytic pathway), and Bernard L. Horecker, Efraim Racker, and Melvin Calvin (who isolated the non-oxidative carbon-shuffling enzymes transketolase and transaldolase and demonstrated their mirror-image participation in the photosynthetic Calvin–Benson–Bassham cycle).

Unlike catabolic pathways driven by cellular energy charge ([AMP]/[ATP]), flux through the pentose phosphate pathway is partitioned dynamically between an irreversible oxidative phase and a reversible non-oxidative phase according to a tissue's immediate demand for reducing power (NADPH) versus pentose carbon skeletons (ribose-5-phosphate). Tissues engaged in rapid lipid or steroid synthesis—such as liver, lactating mammary gland, adipose tissue, and adrenal cortex—channel up to 20–30% of their glucose flux through the oxidative PPP, whereas mature mammalian erythrocytes (red blood cells), which lack nuclei and mitochondria, depend exclusively on the PPP for 100% of the NADPH required to prevent oxidative hemolysis.

---

1. The Irreversible Oxidative Phase

The oxidative branch converts one molecule of the six-carbon hexose D-glucose-6-phosphate into one molecule of the five-carbon ketose D-ribulose-5-phosphate, liberating C-1 as CO₂ and reducing two molecules of NADP⁺ to NADPH across three enzymatic steps:

1. Oxidation of Glucose-6-Phosphate (Committed Rate-Limiting Step): Catalyzed by glucose-6-phosphate dehydrogenase (G6PD) (EC 1.1.1.49), a Mg²⁺-dependent homodimer or homotetramer containing a tightly bound structural NADP⁺ molecule in addition to its catalytic NADP⁺ cleft. G6PD stereospecifically transfers a hydride ion (H⁻) from C-1 of β-D-glucopyranose-6-phosphate to NADP⁺, forming the cyclic ester 6-phosphoglucono-δ-lactone and the first molecule of NADPH + H⁺ (Δ*G*°' ≈ −17.6 kJ mol⁻¹). G6PD is strongly inhibited competitively by its product NADPH (K_i ≈ 7 μM) and allosterically activated by a rising [NADP⁺]/[NADPH] ratio; in resting liver cytosol where [NADPH]/[NADP⁺] ≈ 100:1, G6PD is nearly completely inhibited until anabolic or oxidative consumption of NADPH regenerates NADP⁺.
2. Lactone Hydrolysis: Although 6-phosphoglucono-δ-lactone undergoes slow spontaneous non-enzymatic hydrolysis, 6-phosphogluconolactonase (EC 3.1.1.31) accelerates ring opening by several orders of magnitude to yield the linear aldonic acid 6-phospho-D-gluconate, preventing the reactive electrophilic δ-lactone from non-specifically acylating cellular nucleophilic proteins.
3. Oxidative Decarboxylation: Catalyzed by 6-phosphogluconate dehydrogenase (6PGD) (EC 1.1.1.44), which uses a second molecule of NADP⁺ to oxidize the C-3 hydroxyl group of 6-phosphogluconate into a transient β-keto acid intermediate (3-keto-6-phosphogluconate) that spontaneously decarboxylates at C-1 to release CO₂ and generate D-ribulose-5-phosphate (Ru5P) plus a second molecule of NADPH + H⁺.

Summing the three reactions yields the net stoichiometry of the oxidative phase (overall standard transformed Gibbs free energy Δ*G*°' ≈ −51 kJ mol⁻¹):

D-Glucose-6-phosphate + 2 NADP⁺ + H₂O → D-Ribulose-5-phosphate + CO₂ + 2 NADPH + 2 H⁺

2. The Reversible Non-Oxidative Phase

The non-oxidative branch operates near thermodynamic equilibrium (Δ*G* ≈ 0) and interconverts five-carbon pentose phosphates with three-carbon (glyceraldehyde-3-phosphate, G3P) and six-carbon (fructose-6-phosphate, F6P) intermediates of glycolysis. First, two isomerases partition D-ribulose-5-phosphate into the substrates required for nucleotide synthesis and carbon reshuffling:

• Ribose-5-phosphate isomerase (RPI): Converts the ketose D-ribulose-5-phosphate ⇌ the aldose D-ribose-5-phosphate (R5P) via an enediol intermediate. R5P is subsequently phosphorylated by phosphoribosyl pyrophosphate (PRPP) synthetase using ATP to form 5-phosphoribosyl-1-pyrophosphate (PRPP), the activated precursor for purine, pyrimidine, histidine, and tryptophan synthesis.
• Ribulose-5-phosphate 3-epimerase (RPE): Epimerizes the chiral configuration at C-3 of D-ribulose-5-phosphate ⇌ D-xylulose-5-phosphate (Xu5P).

When the cell produces more pentose phosphates than required for nucleic acid synthesis, three molecules of Ru5P (isomerized into 2 Xu5P + 1 R5P, totaling 15 carbons) are rearranged into two hexoses (2 F6P, 12 carbons) and one triose (1 G3P, 3 carbons) by the sequential action of two carbon-transfer enzymes:

In transketolase, the deprotonated thiazolium C-2 ylide carbanion of thiamine pyrophosphate (TPP) attacks the C-2 carbonyl of a ketose donor (Xu5P), cleaving the C-2–C-3 bond to release an aldose (G3P) while stabilizing a resonance-delocalized two-carbon α-carbanion (active glycolaldehyde) that condenses with an aldose acceptor (R5P or E4P). Clinically, measurement of erythrocyte transketolase activation by exogenous TPP serves as the gold-standard biochemical assay for thiamine (vitamin B₁) deficiency in Wernicke–Korsakoff syndrome and beriberi. Conversely, transaldolase lacks a prosthetic group and instead uses the ε-amino group of an active-site lysine residue to form a covalent protonated Schiff base with C-2 of sedoheptulose-7-phosphate, serving as an electron sink to transfer a three-carbon dihydroxyacetone moiety onto G3P to yield F6P and erythrose-4-phosphate.

---

Because the non-oxidative reactions are freely reversible, cells operate the PPP in four distinct stoichiometric modes tailored to physiological demand:

1. Mode 1 — Balanced Requirement for Both Ribose-5-Phosphate and NADPH: Only the oxidative phase plus ribose-5-phosphate isomerase operate:

G6P + 2 NADP⁺ + H₂O → Ribose-5-phosphate + 2 NADPH + 2 H⁺ + CO₂

1. Mode 2 — Much More Ribose-5-Phosphate Than NADPH Needed (Rapidly Dividing Cells): When DNA/RNA synthesis outpaces NADPH consumption, G6PD is inhibited by high [NADPH]. Fructose-6-phosphate and glyceraldehyde-3-phosphate are drawn directly from glycolysis into the non-oxidative branch running in reverse via transketolase and transaldolase:

5 Glucose-6-phosphate + ATP → 6 Ribose-5-phosphate + ADP + H⁺

1. Mode 3 — Much More NADPH Than Ribose-5-Phosphate Needed (Adipose, Mammary, Erythrocytes): Six G6P molecules pass through the oxidative branch (yielding 6 Ru5P + 12 NADPH + 6 CO₂); the 6 Ru5P are rearranged by the non-oxidative branch into 4 F6P + 2 G3P, which are converted back into 5 G6P via phosphoglucose isomerase, aldolase, and fructose-1,6-bisphosphatase. The net cycle completely oxidizes 1 glucose molecule to 6 CO₂ while generating 12 NADPH:

Glucose-6-phosphate + 12 NADP⁺ + 7 H₂O → 6 CO₂ + 12 NADPH + 12 H⁺ + P_i

1. Mode 4 — Both NADPH and ATP (Pyruvate) Needed: The 4 F6P and 2 G3P generated in Mode 3 enter lower glycolysis rather than gluconeogenesis, producing pyruvate, NADH, and ATP alongside NADPH:

3 Glucose-6-phosphate + 6 NADP⁺ + 5 NAD⁺ + 5 P_i + 8 ADP → 5 Pyruvate + 3 CO₂ + 6 NADPH + 5 NADH + 8 ATP + 2 H₂O + 8 H⁺

---

In mammalian cells—and uniquely in mature anucleate erythrocytes, which lack mitochondria and depend entirely on the oxidative PPP for NADPH—cytosolic NADPH is essential to maintain the tripeptide glutathione (γ-L-glutamyl-L-cysteinylglycine, GSH) in its reduced sulfhydryl state (~5 mM, with [GSH]/[GSSG] > 100:1). Glutathione peroxidase (a selenoenzyme containing selenocysteine) detoxifies hydrogen peroxide (H₂O₂) and lipid hydroperoxides generated by oxygen transport:

2 GSH + H₂O₂ → GSSG (oxidized disulfide) + 2 H₂O

The flavoprotein glutathione reductase then uses NADPH from G6PD to regenerate reduced GSH:

GSSG + NADPH + H⁺ → 2 GSH + NADP⁺

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzymopathy, affecting over 400 million people worldwide. Because the G6PD gene resides on the distal long arm of the X chromosome (Xq28), the condition follows X-linked inheritance, predominantly manifesting in hemizygous males. Over 200 polymorphic missense variants reduce G6PD catalytic stability (accelerating the exponential decay of enzyme activity, A(t) = A₀ exp(−*kt*), across the 120-day lifespan of an erythrocyte, which cannot synthesize new protein). Most G6PD-deficient individuals are asymptomatic under basal conditions, but ingestion of oxidative triggers—including the antimalarial drug primaquine, sulfonamide antibiotics, naphthalene, or the pyrimidine glycosides vicine and convicine in fava beans (favism)—overwhelms their residual NADPH capacity. Depletion of GSH allows H₂O₂ to oxidize hemoglobin sulfhydryl groups into insoluble denatured aggregates termed Heinz bodies, which are pitted by splenic macrophages ("bite cells") and cause acute intravascular hemolytic anemia.

Strikingly, the geographical distribution of G6PD deficiency alleles (such as the African G6PD A− variant and the severe G6PD Mediterranean variant) overlaps closely with endemic Plasmodium falciparum malaria belts, representing a classic example of heterozygote advantage and balancing selection: elevated oxidative stress inside G6PD-deficient erythrocytes impairs the intracellular growth of the malaria parasite and accelerates early phagocytic clearance of ring-stage parasitized red blood cells.

---

Why do cells need both NADH and NADPH instead of using a single nicotinamide coenzyme?

NAD⁺ and NADP⁺ differ only by a single 2'-phosphate group on the adenosine ribose ring, which does not alter the redox potential of the nicotinamide ring (*E*°' ≈ −0.32 V for both). However, this 2'-phosphate tag allows enzymes to segregate the two pools into opposite thermodynamic states: cells maintain a high [NAD⁺]/[NADH] ratio (~700:1 in cytosol) to drive oxidative catabolism (glycolysis and the TCA cycle), while simultaneously maintaining a low [NADP⁺]/[NADPH] ratio (~1:100) via the pentose phosphate pathway to drive reductive biosynthesis and antioxidant defense.

How can rapidly dividing cells synthesize ribose-5-phosphate without producing excess NADPH?

When rapidly proliferating cells require large quantities of ribose-5-phosphate for DNA and RNA synthesis without a matching demand for NADPH, elevated cytosolic [NADPH] competitively inhibits glucose-6-phosphate dehydrogenase (G6PD), shutting down the irreversible oxidative phase. Instead, the cell draws fructose-6-phosphate and glyceraldehyde-3-phosphate directly from glycolysis and runs the reversible non-oxidative transketolase and transaldolase reactions backward to convert 5 hexose phosphates into 6 ribose-5-phosphate molecules.

Why are red blood cells uniquely vulnerable to glucose-6-phosphate dehydrogenase (G6PD) deficiency?

Mature mammalian erythrocytes expel their nuclei, ribosomes, and mitochondria during differentiation. Because they lack mitochondria, the pentose phosphate pathway is their sole enzymatic source of NADPH, and because they lack ribosomes, they cannot synthesize fresh G6PD to replace unstable mutant enzyme molecules that degrade over the cell's 120-day lifespan. When exposed to primaquine or fava beans, aged G6PD-deficient erythrocytes cannot regenerate reduced glutathione (GSH), leading to hemoglobin cross-linking into Heinz bodies and hemolytic anemia.

---

1. Horecker, B. L. (2002). "The pentose phosphate pathway." The Journal of Biological Chemistry, 277(50), 47965–47971. https://doi.org/10.1074/jbc.X200007200
2. Cappellini, M. D., & Fiorelli, G. (2008). "Glucose-6-phosphate dehydrogenase deficiency." The Lancet, 371(9606), 64–74. https://doi.org/10.1016/S0140-6736(08)60073-260073-2)
3. Stincone, A., Prigione, A., Cramer, T., Wamelink, M. M. C., Campbell, K., Cheung, E., Olin-Sandoval, V., Grüning, N.-M., Krüger, A., Tauqeer Alam, M., Keller, M. A., Breitenbach, M., Brindle, K. M., Rabinowitz, J. D., & Ralser, M. (2015). "The return of metabolism: biochemistry and physiology of the pentose phosphate pathway." Biological Reviews, 90(3), 927–963. https://doi.org/10.1111/brv.12140
4. Luzzatto, L., Ally, M., & Notaro, R. (2020). "Glucose-6-phosphate dehydrogenase deficiency." Blood, 136(11), 1225–1240. https://doi.org/10.1182/blood.2019000944